Abstract:ID 87867 Poster Board 474 The combined inhibition of soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) represents a novel approach to non-opioid pain management, drawing from the known functions of these enzymes in pain and inflammatory pathways. Using multi-target directed ligands (MTDLs), a medicinal chemistry approach where a single drug modulates two or more biological targets simultaneously, our lab previously identified several benzothiazole-phenyl MTDLs with potent dual sEH and FAAH inhibition. Here, we report several in vivo evaluations of our previously identified dual sEH/FAAH inhibitor SP 4-5, the data received from National Institute of Mental Health's Psychoactive Drug Screening Program (PDSP) and a follow-up structure-activity relationship (SAR) study of quinolinyl-phenyl-based MTDLs that were synthesized using a microwave-assisted Suzuki coupling reaction. SP 4-5 was evaluated against persistent inflammatory pain. An intraplantar injection of Complete Freund's Adjuvant (CFA) was used to induce hindpaw inflammation. 1 and 3 mg/kg SP4-5 were administered 24 hours after inflammation. Neither dose alleviated mechanical or thermal hypersensitivity. However, when administered 2.5 hours after CFA, 3 mg/kg SP4-5 increased mechanical withdrawal thresholds indicating antinociception. In addition, PDSP screening showed that SP 4-5 does not bind to delta, mu and kappa opioid receptors. Our SAR study showed that quinoline moiety can successfully replace benzothiazole ring yielding potent compounds in human FAAH and human, rat, and mouse sEH inhibition assays. The most potent dual sEH/FAAH inhibitor identified in this study, JA112, showed inhibition potency in the low nanomolar range (1.7 nM -17.2 nM) for human FAAH, human sEH, rat sEH and mouse sEH enzymes. JA-112 was evaluated for its ability to reverse acute inflammatory induced by an intraplantar injection of dilute formalin. This revealed that JA-112 produces antinociception against formalin-induced inflammatory pain. Further, the differences observed between Phase 1 and Phase 2 of the Formalin Test indicate that JA-112 produces antinociception in a manner consistent with drugs that prevent pro-inflammatory states such as non-steroidal anti-inflammatory drugs (i.e., in non-opioid manner). Future experiments will investigate the effects of JA-112 against persistent inflammatory pain states and determine any adverse effects. Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under award number 1 R16GM149204-01.

Clinical validation of a fast-acting acetaminophen: a randomized, active and placebo controlled dental pain study

Analgesic onset and efficacy of a fast-acting formulation of acetaminophen in a postoperative dental impaction pain model

Comparison of a novel fast-dissolving acetaminophen tablet formulation (FD-APAP) and standard acetaminophen tablets using gamma scintigraphy and pharmacokinetic studies

Evaluation of onset of pain relief from micronized aspirin in a dental pain model

Pain Reduction of Ibuprofen Sodium Dihydrate Alone and in Combination with Acetaminophen in an Untreated Endodontic Pain Model: A Randomized, Double-blind Investigation

Dissolution and pharmacokinetics of a novel micronized aspirin formulation

Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid–aspirin complex: results of a randomized, crossover, bioequivalence study

Randomized, double‐blind, phase 1a single‐ascending dose and food effect studies assessing safety and pharmacokinetics of EC5026 in healthy volunteers

Clinical Evaluation of a Novel Technology for Oral Patient-Controlled Analgesia, the PCoA® Acute Device, for Hospitalized Patients with Postoperative Pain, in Pilot Feasibility Study

Nonclinical safety assessment of PF614: A novel TAAP prodrug of oxycodone for chronic pain indication

Clinical evaluation of PF614, a novel TAAP prodrug of oxycodone, versus OxyContin in a multi‐ascending dose study with a bioequivalence arm in healthy volunteers

Multitarget-Directed Ligands with Soluble Epoxide Hydrolase and Fatty Acid Amide Hydrolase Inhibitory Activities for Treatment of Chronic Pain

Analgesic efficacy of morphine sulfate immediate release vs. oxycodone/acetaminophen for acute pain in the emergency department

Acetaminophen: Ancient drug with a novel analgesic mechanism of action

Optimization and comparison of unidirectional lidocaine-loaded buccal patch with the articaine-loaded buccal patch to reduce injection pain and increment of patients' compliance in dental procedures: A double-blind randomized controlled trial

A randomized, double-blind, placebo-controlled trial of paracetamol and ketoprofren lysine salt for pain control in children with pharyngotonsillitis cared by family pediatricians

Efficacy and safety of 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1, 2-benzothiazin-3-carboxamide 1,1-dioxide, a rapid-acting meloxicam formulation, for analgesia after orthopaedic surgery under general anaesthesia: a randomized controlled trial

Analgesic Effect of Acetaminophen: A Review of Known and Novel Mechanisms of Action

Oxaprozin: kinetic and dynamic profile in the treatment of pain

The pharmacokinetics, efficacy, and safety of a novel selective‐dose cannabis inhaler in patients with chronic pain: A randomized, double‐blinded, placebo‐controlled trial

Exploring acetaminophen prodrugs and hybrids: a review